Trial · NCT01092403
Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma
NCT01092403, Phase 2, Completed, Asmacure Ltée
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma. Trials, record NCT01092403. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01092403
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma
- NCT number
- NCT01092403
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 24 participants, actual
- Lead sponsor
- Asmacure Ltée
- Conditions
- Mild Allergic Asthma
- Interventions
- ASM-024, Placebo
- First posted
- 2010-03-25
- Last updated
- 2012-01-26
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Late asthmatic response (LAR) | Day 8 of each treatment period | LAR as measured by the peak drop in FEV1 from 3 to 7 hours post-allergen challenge |
| Primary | Early asthmatic response (EAR) | Day 8 of every treatment period | EAR as measured by the peak drop in FEV1 from 0 to 3 hours post-allergen challenge |
| Primary | Airway hyperresponsiveness | Days -1, 7 and 9 of each treatment period | Difference between methacholine PC20 measured 24 hours following allergen challenge and methacholine PC20 measured 24 hours before allergen challenge |
| Primary | Safety and tolerability | Physical examination: Day 9, vital signs: Days -1, 1, 7, 8 and 9; twelve-lead ECG: Days 1, 7, 8 and 9 , AEs throughout the study, safety laboratory assessments Day 1 and 9 and Chest X-Ray: Day 9 of the final treatment period | |
| Secondary | LAR's FEV1 AUC | Day 8 of every treatment period | From 3 to 7 hours post-allergen challenge |
| Secondary | FEV1 | Day 9 | 24 hours post-allergen challenge |
| Secondary | EAR's FEV1 AUC | Day 8 | From 0 to 3 hours post-allergen challenge |
| Secondary | Change in FEV1 | Days 1, 7, 8 and 9 | Before inhalation of ASM-024 and as soon as possible following inhalation of ASM-024 |
| Secondary | Induced sputum eosinophil count and eosinophil and neutrophil percentages | Days -1, 7 and 9 of every Treatment Period | |
| Secondary | Blood eosinophil count | Days -1 and 9 of every Treatment Period |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01092403
GET https://conductscience.org/api/trials/v1/NCT01092403/registered